MintNeuro announced a multi‑year commercial supply agreement with Motif Neurotech this week to deliver its ultra‑low‑power neural sensing and stimulation chips for Motif’s DOT implant platform.

Under the framework, MintNeuro will supply chips for Motif’s DOT device across pre‑clinical work, early clinical studies and pivotal trials, subject to Motif’s development and regulatory milestones. The DOT implant, described by Motif as a blueberry‑sized system, has U.S. FDA clearance to begin a clinical trial in treatment‑resistant depression and can be placed via a brief outpatient procedure without direct brain exposure.

MintNeuro said the deal builds on more than a year of joint architecture design and hardware validation using its chips in Motif’s pre‑clinical work. The multi‑year structure could provide revenue visibility linked to Motif’s program timeline, though no financial terms were disclosed.

The partnership also connects to the U.K. ARIA‑funded Brain Mesh project, a £4.7 million effort targeting distributed networks of ultra‑small wireless neural implants. MintNeuro said involvement in that ecosystem supports its chip miniaturization roadmap and regulatory readiness.

MintNeuro CEO Dorian Haci represented the company in person at the 17th World Congress of the International Neuromodulation Society in Lisbon and at Deep Tech Momentum 2026 in Berlin. At both events the company presented its implantable hardware platform and met clinicians, engineers and industry partners focused on minimally invasive stimulation and closed‑loop systems.

No additional commercial contracts or financial details were disclosed. Together, the Motif supply agreement and conference activity increase MintNeuro’s visibility as a semiconductor supplier for implantable neuromodulation and therapeutic BCI projects.

Photo credit: blog.tipranks.com

Tags: implantable BCI, neuromodulation, semiconductor ASICs, treatment-resistant depression

Topics: Neurotech industry & startups, Neuromodulation, Neuroprosthetics & neural implants